0001493152-24-031161.txt : 20240812 0001493152-24-031161.hdr.sgml : 20240812 20240812081537 ACCESSION NUMBER: 0001493152-24-031161 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240812 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240812 DATE AS OF CHANGE: 20240812 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lucid Diagnostics Inc. CENTRAL INDEX KEY: 0001799011 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 825488042 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40901 FILM NUMBER: 241194819 BUSINESS ADDRESS: STREET 1: 360 MADISON AVENUE STREET 2: 25TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 212 949 4319 MAIL ADDRESS: STREET 1: 360 MADISON AVENUE STREET 2: 25TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10017 8-K 1 form8-k.htm
false 0001799011 0001799011 2024-08-12 2024-08-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): August 12, 2024

 

LUCID DIAGNOSTICS INC.
(Exact Name of Registrant as Specified in Charter)

 

Delaware   001-40901   82-5488042

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

360 Madison Avenue, 25th Floor, New York, New York   10017
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (917) 813-1828

 

N/A
(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, Par Value $0.001 Per Share   LUCD   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 2.02 Results of Operations and Financial Condition.

 

On August 12, 2024, the Company issued a press release announcing financial results for its fiscal quarter ended June 30, 2024 and providing a business update. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated herein by reference.

 

Item 7.01. Regulation FD Disclosure.

 

The disclosure set forth under Item 2.02 is incorporated herein by reference.

 

The information furnished under Items 2.02 and 7.01, including the exhibit related thereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any disclosure document of the Company, except as shall be expressly set forth by specific reference in such document.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits:

 

Exhibit No.   Description
99.1   Press release.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 2 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: August 12, 2024 LUCID DIAGNOSTICS INC.
     
  By: /s/ Dennis McGrath
    Dennis McGrath
    Chief Financial Officer

 

 3 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

Lucid Diagnostics Provides Business Update and Second Quarter 2024 Financial Results

 

EsoGuard® test volume increased 31 percent quarterly; 44 percent annually

 

Clinical data now well-positioned for final push towards broad coverage and reimbursement

 

Over 50 high-volume #CheckYourFoodTube Precancer Testing Events in 2Q24, including first with upfront contracted payment

 

Conference call and webcast to be held today, August 12th at 8:30 AM EDT

 

NEW YORK, August 12, 2024 - Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today provided a business update for the Company and presented financial results for the three months ended June 30, 2024.

 

Conference Call and Webcast

 

The webcast will take place on Monday, August 12, 2024, at 8:30 AM and will be accessible in the investor relations section of the Company’s website at luciddx.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name “Lucid Diagnostics Business Update” to join.

 

Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company’s website at luciddx.com.

 

Business Update Highlights

 

“I am very pleased with the excellent progress Lucid has made on multiple fronts during the second quarter and recent weeks, specifically the progress made related to EsoGuard’s clinical data,” said Lishan Aklog, M.D., Lucid’s Chairman and Chief Executive Officer. “We are now fully armed with a complete body of clinical data and well-positioned for our final push towards broad coverage and reimbursement to drive EsoGuard revenue and revenue growth.”

 

 
 

 

Highlights from the second quarter and recent weeks:

 

●For the quarter, EsoGuard® Esophageal DNA Test revenue was $1.0M, which was flat compared to 1Q24 and represents a 514 percent annual increase from 2Q23.

 

●Lucid’s CLIA-certified clinical laboratory performed 3,147 commercial EsoGuard tests in 2Q24, a single-quarter record, which represents a 31 percent increase sequentially from 1Q24 and a 44 percent annual increase from 2Q23.

 

●Released ENVET-BE clinical utility study positive data showing that triaging with a noninvasive EsoGuard test results in a 2.4-fold increased positive yield of invasive endoscopy.

 

●Released ESOGUARD BE-1 clinical validation study positive data showing excellent EsoGuard sensitivity of 88% and NPV of 99%.

 

●Held productive meeting with CMS Medicare Administrative Contractor (MAC) Palmetto GBA’s Molecular Diagnostics Program (MolDX) focused on EsoGuard’s clinical data.

 

●Held first major #CheckYourFoodTube Precancer Testing Event with upfront contracted payment.

 

●American Foregut Society published formal statement strongly advocating for commercial payor coverage of EsoGuard to align with guidelines and biomarker legislation.

 

●Continuous revenue cycle management improvements, including prior authorization appeals, physician advocacy, etc., while maintaining stable out-of-network allowed amounts.  

 

●Robust pipeline of direct contracting engagements with benefits brokers, third-party administrators, and self-insured entities.

 

●Actively executing on aggressive market access strategy focused on securing medical policy coverage with regional plans in biomarker legislation states and pilots with national plans.

 

Financial Results

 

●For the three months  ended June 30, 2024, EsoGuard related revenues were $1.0 million. Operating expenses were approximately $12.2 million, which included stock-based compensation expenses of $1.2 million. GAAP net loss attributable to common stockholders was approximately $11.0   million or $(0.23) per common share.

 

●As shown below and for the purpose of illustrating the effect of stock-based compensation and other non-cash income and expenses on the Company’s financial results, the Company’s non-GAAP adjusted loss for the three months ended June 30, 2024 was approximately $9.7 million or $(0.20) per common share.

 

 
 

 

●Lucid had cash and cash equivalents of $24.9 million as of June 30, 2024, compared to $18.9 million as of December 31, 2023. During the quarter ended June 30, 2024, he Company issued Series B-1 Convertible Preferred Stock Series resulting in gross proceeds of approximately $11.6 million.

 

●The unaudited financial results for the three and six months ended June 30, 2024, were filed with the SEC on Form 10-Q on August 12, 2024, and available at www.luciddx.com or www.sec.gov.

 

Lucid Non-GAAP Measures

 

●To supplement our unaudited financial results presented in accordance with U.S. generally accepted accounting principles (GAAP), management provides certain non-GAAP financial measures of the Company’s financial results. These non-GAAP financial measures include net loss before interest, taxes, depreciation, and amortization (EBITDA), and non-GAAP adjusted loss, which further adjusts EBITDA for stock-based compensation expense and other non-cash income and expenses, if any. The foregoing non-GAAP financial measures of EBITDA and non-GAAP adjusted loss are not recognized terms under U.S. GAAP.

 

●Non-GAAP financial measures are presented with the intent of providing greater transparency to the information used by us in our financial performance analysis and operational decision-making. We believe these non-GAAP financial measures provide meaningful information to assist investors, shareholders, and other readers of our unaudited financial statements in making comparisons to our historical financial results and analyzing the underlying performance of our results of operations. These non-GAAP financial measures are not intended to be, and should not be, a substitute for, considered superior to, considered separately from, or as an alternative to, the most directly comparable GAAP financial measures.

 

●Non-GAAP financial measures are provided to enhance readers’ overall understanding of our current financial results and to provide further information for comparative purposes. Management believes the non-GAAP financial measures provide useful information to management and investors by isolating certain expenses, gains, and losses that may not be indicative of our core operating results and business outlook. Specifically, the non-GAAP financial measures include non-GAAP adjusted loss, and its presentation is intended to help the reader understand the effect of the loss on the issuance or modification of convertible securities, the periodic change in fair value of convertible securities, the loss on debt extinguishment, and the corresponding accounting for non-cash charges on financial performance. In addition, management believes non-GAAP financial measures enhance the comparability of results against prior periods.

 

 
 

 

●A reconciliation to the most directly comparable GAAP measure of all non-GAAP financial measures included in this press release for the three and six months ended June 30, 2024, and 2023 are as follows:

 

Condensed consolidated statements of operations (unaudited)

 

(in thousands except per-share amounts)  For the three months ended
June 30,		   For the six months ended
June 30,		 
   2024   2023   2024   2023 
                 
Revenue  $976   $159   $1,977   $605 
                     
Operating expenses   12,168    11,743    23,960    26,505 
Other (Income) expense   (187)   (203)   (366)   1,728 
Net Loss   (11,005)   (11,381)   (21,617)   (27,628)
Net income (loss) per common share, basic and diluted  $(0.23)  $(0.27)  $(0.62)  $(0.40)
Net loss attributable to common stockholders   (11,005)   (11,381)   (29,113)   (27,628)
Preferred Stock dividends and deemed dividends   —    —    7,496    — 
Net income (loss) as reported   (11,005)   (11,381)   (21,617)   (27,628)
Adjustments:                    
Depreciation and amortization expense1   229    633    730    1,245 
Interest expense, net2   (101)   87    (157)   43 
EBITDA   (10,877)   (10,661)   (21,044)   (26,340)
                     
Other non-cash or financing related expenses:                    
Stock-based compensation expense3   1,201    1,399    2,135    4,607 
ResearchDx acquisition paid in stock1   —    —    —    713 
Operating expenses issued in stock1   90    23    113    23 
Change in FV convertible debt2   (599)   (290)   (890)   499 
Offering costs convertible debt2   —    —    —    1,186 
Debt extinguishments loss - Senior Secured Convertible Note2   513    —    681    — 
Non-GAAP adjusted (loss)  $(9,672)  $(9,529)  $(19,005)  $(19,312)
Basic and Diluted shares outstanding   48,212    41,834    46,613    41,405 
Non-GAAP adjusted (loss) income per share  $(0.20)  $(0.23)  $(0.41)  $(0.47)

 

1 Included in general and administrative expenses in the financial statements.

 

2 Included in other income and expenses.

 

3 Stock-based compensation (“SBC”) expense included in operating expenses is detailed as follows in the table below by category within operating expenses for the non-GAAP Net operating expenses:

 

 
 

 

Reconciliation of GAAP Operating Expenses to Non-GAAP Net Operating Expenses

 

(in thousands except per-share amounts)  For the three months ended
June 30,		   For the six months ended
June 30,		 
   2024   2023   2024   2023 
Cost of revenues  $1,614   $1,549   $3,269   $2,887 
Stock-based compensation expense3   (44)   (25)   (80)   (44)
Net cost of revenues   1,570    1,524    3,189    2,843 
                     
Amortization of intangible assets   105    505    477    1,010 
                     
Sales and marketing   4,210    4,032    8,404    8,159 
Stock-based compensation expense3   (365)   (367)   (715)   (723)
Net sales and marketing   3,845    3,665    7,689    7,436 
                     
General and administrative   4,867    3,830    8,937    10,730 
Depreciation expense   (124)   (128)   (253)   (235)
RDx Settlement in Stock   —    —    —    (713)
Operating expenses issued in stock   (90)   (23)   (113)   (23)
Stock-based compensation expense3   (610)   (844)   (941)   (3,512)
Net general and administrative   4,043    2,835    7,630    6,247 
                     
Research and development   1,372    1,827    2,873    3,719 
Stock-based compensation expense3   (182)   (163)   (399)   (328)
Net research and development   1,190    1,664    2,474    3,391 
                     
Total operating expenses   12,168    11,743    23,960    26,505 
Depreciation and amortization expense   (229)   (633)   (730)   (1,245)
RDx Settlement in Stock   —    —    —    (713)
Operating expenses issued in stock   (90)   (23)   (113)   (23)
Stock-based compensation expense3   (1,201)   (1,399)   (2,135)   (4,607)
Net operating expenses  $10,648   $9,688   $20,982   $19,917 

 

About EsoGuard and EsoCheck

 

Millions of patients with gastroesophageal reflux disease (GERD) are at risk of developing esophageal precancer and a highly lethal form of esophageal cancer (“EAC”). Over 80 percent of EAC patients die within five years of diagnosis, making it the second most lethal cancer in the U.S. The mortality rate is high even in those diagnosed with early stage EAC. The U.S. incidence of EAC has increased 500 percent over the past four decades, while the incidences of other common cancers have declined or remained flat. In nearly all cases, EAC silently progresses until it manifests itself with new symptoms of advanced disease. All EAC is believed to arise from esophageal precancer, which occurs in approximately 5 percent to 15 percent of at-risk GERD patients. Early esophageal precancer can be monitored for progression to late esophageal precancer which can be cured with endoscopic esophageal ablation, reliably halting progression to cancer.

 

 
 

 

Esophageal precancer screening is already recommended by clinical practice guidelines for the millions of GERD patients with multiple risk factors, including age over 50 years, male sex, White race, obesity, smoking history, and a family history of esophageal precancer or cancer. Unfortunately, fewer than 10 percent of those recommended for screening undergo traditional invasive endoscopic screening. The profound tragedy of an EAC diagnosis is that death could likely have been prevented if the at-risk GERD patient had been screened and then undergone surveillance and curative treatment at the precancer stage.

 

The only missing element for a viable esophageal cancer prevention program has been the lack of an easily-accessible, in-office screening tool that can detect esophageal precancer. Lucid believes EsoGuard, performed on samples collected non-endoscopically with EsoCheck, is the missing element – the first and only commercially available test capable of serving as a widespread screening tool to prevent esophageal cancer deaths through the early detection of esophageal precancer in at-risk GERD patients. An updated American College of Gastroenterology (ACG) clinical practice guideline and an American Gastroenterological Association (AGA) clinical practice update both endorse non-endoscopic biomarker tests as an acceptable alternative to costly and invasive endoscopy for esophageal precancer screening. EsoGuard is the only such test currently available in the United States.

 

EsoGuard is a Next Generation Sequencing (NGS) based DNA methylation assay performed on surface esophageal cells collected with EsoCheck, which quantifies methylation at 31 sites on two genes, Vimentin (VIM) and Cyclin A1 (CCNA1). The assay was initially evaluated in a 408-patient, multicenter, case-control study published in Science Translational Medicine and showed greater than 90 percent sensitivity and specificity at detecting esophageal precancer and cancer.

 

EsoCheck is a CE Marked and FDA 510(k) cleared noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in a less than three-minute office procedure. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to gently swab surface esophageal cells. When vacuum suction is applied, the balloon and sampled cells are pulled into the capsule, protecting them from contamination and dilution by cells outside of the targeted region during device withdrawal. Lucid believes this proprietary Collect+Protect™ technology makes EsoCheck the only noninvasive esophageal cell collection device capable of such anatomically targeted and protected sampling. The sample is sent by overnight express mail to Lucid’s CLIA-certified, CAP-accredited, NYS CLEP approved laboratory, LucidDx Labs, for EsoGuard testing.

 

 
 

 

About Lucid Diagnostics

 

Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. Lucid is focused on the millions of patients with GERD, also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid’s EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device - the first and only commercially available tools designed with the goal of preventing esophageal cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.

 

For more information, please visit luciddx.com and for more information about its parent company PAVmed, please visit pavmed.com.

 

Forward-Looking Statements

 

This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of Lucid Diagnostics’ management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of Lucid Diagnostics’ common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance Lucid Diagnostics’ products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from Lucid Diagnostics’ clinical and preclinical studies; whether and when Lucid Diagnostics’ products are cleared by regulatory authorities; market acceptance of Lucid Diagnostics’ products once cleared and commercialized; Lucid Diagnostics’ ability to raise additional funding as needed; and other competitive developments. These factors are difficult or impossible to predict accurately and many of them are beyond Lucid Diagnostics’ control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect Lucid Diagnostics’ future operations, see Part I, Item 1A, “Risk Factors,” in Lucid Diagnostics’ most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, “Risk Factors” in any Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its most recent Annual Report. Lucid Diagnostics disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.

 

Investor and Media Contact

 

Matt Riley

PAVmed and Lucid Diagnostics

610.348.8926

mjr@pavmed.com

 

 

 

 EX-101.SCH 3 lucd-20240812.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 lucd-20240812_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 lucd-20240812_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Cover
Aug. 12, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 12, 2024
Entity File Number 001-40901
Entity Registrant Name LUCID DIAGNOSTICS INC.
Entity Central Index Key 0001799011
Entity Tax Identification Number 82-5488042
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 360 Madison Avenue
Entity Address, Address Line Two 25th Floor
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10017
City Area Code (917)
Local Phone Number 813-1828
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, Par Value $0.001 Per Share
Trading Symbol LUCD
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://luciddiagnostics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm lucd-20240812.xsd lucd-20240812_lab.xml lucd-20240812_pre.xml http://xbrl.sec.gov/dei/2024 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "LUCD", "nsuri": "http://luciddiagnostics.com/20240812", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "lucd-20240812.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "labelLink": { "local": [ "lucd-20240812_lab.xml" ] }, "presentationLink": { "local": [ "lucd-20240812_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 24 }, "report": { "R1": { "role": "http://luciddiagnostics.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-08-12", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-08-12", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://luciddiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001493152-24-031161-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-031161-xbrl.zip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form8-k_htm.xml IDEA: XBRL DOCUMENT 0001799011 2024-08-12 2024-08-12 iso4217:USD shares iso4217:USD shares false 0001799011 8-K 2024-08-12 LUCID DIAGNOSTICS INC. DE 001-40901 82-5488042 360 Madison Avenue 25th Floor New York NY 10017 (917) 813-1828 false false false false Common Stock, Par Value $0.001 Per Share LUCD NASDAQ true false